Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT03645928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN 144/LN-145/LN-145-S1) in Patients With Solid Tumors
Study identification
- NCT ID
- NCT03645928
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Enrollment
- 225 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Ipilimumab Drug
- LN-145 Biological
- LN-145-S1 Biological
- Lifileucel Biological
- Nab paclitaxel Drug
- Nivolumab Drug
- Nivolumab-relatlimab Drug
- Paclitaxel Drug
- Pembrolizumab Drug
- Pemetrexed Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 6, 2019
- Primary completion
- Feb 19, 2026
- Completion
- Feb 19, 2026
- Last update posted
- May 14, 2026
2019 – 2026
United States locations
- U.S. sites
- 20
- U.S. states
- 14
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Diego | La Jolla | California | 92093 | — |
| University of Southern California | Los Angeles | California | 90007 | — |
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| University of Colorado | Denver | Colorado | 80045 | — |
| Yale University | New Haven | Connecticut | 06520 | — |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | — |
| Orlando Health Cancer Institute | Orlando | Florida | 32610 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Louisville | Louisville | Kentucky | 40292 | — |
| University of Maryland | Baltimore | Maryland | 21201 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Health System | Detroit | Michigan | 48202 | — |
| MD Anderson at Cooper | Camden | New Jersey | 08103 | — |
| Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| University of Cincinnati | Cincinnati | Ohio | 45219 | — |
| Ohio State University | Columbus | Ohio | 43201 | — |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03645928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03645928 live on ClinicalTrials.gov.